On Jun. 16, 2021, RELIEF THERAPEUTICS reported that its collaboration partner, NRx Pharmaceuticals, had announced additional results from the aviptadil U.S. Expanded Access Protocol (EAP). The EAP included 240 patients in the intensive care unit (ICU) with critical COVID-19 respiratory failure requiring either invasive or non-invasive mechanical ventilation, or high flow rate oxygen by nasal cannula, and not eligible for the recently completed phase 2b/3 clinical trial with IV aviptadil.

According to NRxﾒs press release, these EAP data were to be submitted by NRx to the U.S. Food and Drug Administration ﾓreal worldﾔ evidence in support of the findings from the phase 2b/3 trial.